Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
0.00%
)
US TECH 100
28,486.40
(
0.46%
)
Dow Jones
49,526.17
(
0.00%
)
Brent Oil
105.17
(
-2.14%
)
Bitcoin
77,181.24
(
-0.29%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: sluicer post# 158201

Tuesday, 03/12/2013 6:23:15 PM

Tuesday, March 12, 2013 6:23:15 PM

Post# of 257580
AMRN—I have no strong opinion one way or the other on whether Vascepa will get NCE status (and that’s what I’ve said all along). The document you referenced doesn’t add anything probative to the discussion, IMO.

The reason you probably thought I was negative on NCE status is that I’ve said I don’t expect AMRN’s patents to stand up to Paragraph-IV challenges, which can come soon if NCE status is not granted. Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today